•(Bristol Myers Squibb) BMS’s Investment in India: In 2023, BMS announced a $100 million development centre in Hyderabad.
•This addition complements BMS’s existing operations in India, which include commercial activities in Mumbai and an R&D centre in Bengaluru (established in 2008 with Syngene).
•Post-COVID, BMS focused on growing its global talent pool, leading to the establishment of its Hyderabad centre.
•While India has solid regulations ensuring the safety of clinical trial participants, there are areas for improvement.
•For example, India currently does not allow first-in-human trials for drugs discovered outside the country.
•It is suggested that it might be time to revisit this regulation, especially given the rapid pace of innovation in drug development.